Loading stock data…
$2.66-0.19 (-6.67%)
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
BridgeBio Oncology Therapeutics, Inc. in the Healthcare sector is trading at $2.66 with a market capitalization of $265M. Wall Street consensus targets $23.55 (11 analysts), implying a +785.2% move over the next 12 months. The stock is currently near its 52-week low of $2.60, remaining 68.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$60.19M↓ | -$46.18M↓ | -$43.41M↑ | -$49.18M↓ | -$30.09M |
| Net Income | -$56.45M↓ | -$42.11M↓ | -$38.80M↑ | -$44.76M↓ | -$28.43M |
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. Th...